Literature DB >> 16361714

An allogeneic cultured dermal substitute suitable for treating intractable skin ulcers and large skin defects prior to autologous skin grafting: three case reports.

Toshio Hasegawa1, Yasushi Suga, Masayuki Mizoguchi, Shigenori Muramatsu, Yuki Mizuno, Hideoki Ogawa, Kentaro Kubo, Yoshimitsu Kuroyanagi.   

Abstract

Intractable skin ulcers that arise as secondary lesions from disease and full-thickness skin defects that result from skin tumor excision often need autologous skin grafting to close the wound. We developed an allogeneic cultured dermal substitute (CDS) to shorten the time needed to prepare a wound bed suitable for autologous skin grafting. The CDS was prepared by plating normal human fibroblasts on a spongy matrix consisting of hyaluronic acid and atelo-collagen. The allogeneic CDS was then placed on the rinsed wound surface. This procedure was repeated twice a week for up to five weeks, until the wounds were closed by autologous skin grafting. In all three cases, after CDS treatment for two to five weeks, the wound conditions became suitable for skin grafting; these conditions had not been improved by conventional topical treatments, including topical basic fibroblast growth factor (bFGF). Healthy granulation tissue developed rapidly, concomitant with wound size reduction. The present results indicate that CDS is an excellent biological wound dressing for improving wound conditions so that they are suitable for subsequent autologous skin grafting as well as for shortening the treatment duration for skin ulcers and full-thickness skin defects.

Entities:  

Mesh:

Year:  2005        PMID: 16361714     DOI: 10.1111/j.1346-8138.2005.tb00831.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  10 in total

1.  Comparative evaluation of re-epithelialization promoted by fresh or cryopreserved cultured dermal substitute.

Authors:  Naoto Yamada; Eiju Uchinuma; Yasuhiro Matsumoto; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2008-12-17       Impact factor: 1.731

2.  A case of lower-extremity deep burn wounds with periosteal necrosis successfully treated by use of allogenic cultured dermal substitute.

Authors:  Naoki Ohara; Shoji Mihara; Hiroyuki Nihara; Narihiro Akimoto; Naoki Madokoro; Mikio Kawai; Hideki Noda; Michihiro Hide; Yasuhiro Matsumoto; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2010-03-27       Impact factor: 1.731

3.  Skin substitutes based on allogenic fibroblasts or keratinocytes for chronic wounds not responding to conventional therapy: a retrospective observational study.

Authors:  Giorgio Pajardi; Vicenzo Rapisarda; Francesco Somalvico; Andrea Scotti; Giulia Lo Russo; Francesco Ciancio; Arturo Sgrò; Manuela Nebuloni; Raffaele Allevi; Maria L Torre; Emilio Trabucchi; Mario Marazzi
Journal:  Int Wound J       Date:  2014-02-12       Impact factor: 3.315

4.  Treatment of intractable skin ulcers caused by vascular insufficiency with allogeneic cultured dermal substitute: a report of eight cases.

Authors:  Tomonori Taniguchi; Yasuyuki Amoh; Kenichi Tanabe; Kensei Katsuoka; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2011-08-23       Impact factor: 1.731

5.  Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers.

Authors:  Naoto Yamada; Eiju Uchinuma; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2011-12-03       Impact factor: 1.731

Review 6.  Innovative Cell and Platelet Rich Plasma Therapies for Diabetic Foot Ulcer Treatment: The Allogeneic Approach.

Authors:  Maddalena Mastrogiacomo; Marta Nardini; Maria Chiara Collina; Cristiana Di Campli; Gilberto Filaci; Ranieri Cancedda; Teresa Odorisio
Journal:  Front Bioeng Biotechnol       Date:  2022-05-02

7.  Standardization for mass production of allogeneic cultured dermal substitute by measuring the amount of VEGF, bFGF, HGF, TGF-beta, and IL-8.

Authors:  Akiko Hashimoto; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2008-12-17       Impact factor: 1.731

8.  Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers of the lower leg.

Authors:  Naoto Yamada; Eiju Uchinuma; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2008-07-06       Impact factor: 1.731

Review 9.  Cellular human tissue-engineered skin substitutes investigated for deep and difficult to heal injuries.

Authors:  Álvaro Sierra-Sánchez; Kevin H Kim; Gonzalo Blasco-Morente; Salvador Arias-Santiago
Journal:  NPJ Regen Med       Date:  2021-06-17

10.  Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing.

Authors:  Liwen Chen; Edward E Tredget; Philip Y G Wu; Yaojiong Wu
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.